

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10568806
	Filing Date		2006-02-26
	First Named Inventor	Daniel HARARI	
	Art Unit	1646	
	Examiner Name		
	Attorney Docket Number	HARARI=1	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4742003		1998-05-03	DERYNCK et al.			
	2	5783417		1998-07-21	KOMURASAKI et al			
	3	6150502		2000-11-21	STRACHAN			
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9914323	WO		1999-03-25	EPPENBERGER et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568806
Filing Date	2006-02-26
First Named Inventor	Daniel HARARI
Art Unit	1646
Examiner Name	
Attorney Docket Number	HARARI=1

2	0164876	WO	A2	2001-09-07	DECODE GENETICS EHF		<input type="checkbox"/>
3	0164877	WO	A2	2001-09-07	DECODE GENETICS EHF		<input type="checkbox"/>
4	0222685	WO	A2	2002-03-21	KUFE et al.		<input type="checkbox"/>
5	0172781	WO	A2	2001-10-04	WILLIAMS, L.T. et al.		<input type="checkbox"/>
6	0029438	WO	A1	1999-11-19	MILLENNIUM PHARMACEUTICALS INC.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Barbacci, E.G. et al., "The structural basis for the specificity of epidermal growth factor and heregulin binding." J Biol Chem , 270(16):9585-9589, 1995.	<input type="checkbox"/>
	2	Campion, S.R., et al, " Interaction of epidermal growth factor with its receptor. " Prog Nucleic Acid Res Mol Biol , 49:353-383, 1994.	<input type="checkbox"/>
	3	Carpenter, G.,et al., "Epidermal growth factor. " J. Biol. Chem., 265:7709-7712, 1990.	<input type="checkbox"/>
	4	Crovello, C.S. et al., "Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2." J Biol Chem , 273(41):26954-26961, 1998.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568806
Filing Date	2006-02-26
First Named Inventor	Daniel HARARI
Art Unit	1646
Examiner Name	
Attorney Docket Number	HARARI=1

5	Defeo-Jones, D. et al., "A. Substitution of lysine for arginine at position 42 of human transforming growth factor- α eliminates biological activity without changing internal disulfide bonds.", Mol. Cell. Biol., 9:4083-4086, 1989.	<input type="checkbox"/>
6	Engler, D.A. et al., "Critical functional requirements for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation." J. Biol. Chem. , 267:2274-2281, 1992.	<input type="checkbox"/>
7	Falls, D.L. "Neuregulins: functions, forms, and signaling strategies." Exp Cell Res., 284(1):14-30, 2003.	<input type="checkbox"/>
8	Groenen, L.C. et al., "Structure-function relationships for the EGF/TGF- α family of mitogens." Growth Factors, 11:235-257, 1994.	<input type="checkbox"/>
9	Harari, D. et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase." Oncogene, 18(17):2681-2689, 1999	<input type="checkbox"/>
10	Harari, D., et al., "Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.", Oncogene, 19 (53):6102-6114, 2000	<input type="checkbox"/>
11	Harris, R.C. et al., "EGF receptor ligands.", Experimental Cell Research, 284:2-13, 2003	<input type="checkbox"/>
12	Howes, R., et al., "In vivo analysis of Argos structure-function. Sequence requirements for inhibition of the Drosophila epidermal growth factor receptor.", Journal of Biological Chemistry, 273(7):4275-4281, 1998	<input type="checkbox"/>
13	Jin, M.H., et al., "The interaction between the Drosophila secreted protein argos and the epidermal growth factor receptor inhibits dimerization of the receptor and binding of secreted spitz to the receptor.", Mol Cell Biol, 20 (6):2098-2107, 2000.	<input type="checkbox"/>
14	Jones, J.T., et al., "Binding specificities and affinities of egf domains for ErbB receptors.", FEBS Lett, 447(2-3):227-231, 1999	<input type="checkbox"/>
15	Jorissen, R.N., et al., "Epidermal growth factor receptor: mechanisms of activation and signalling", Exp Cell Res, 284 (1):31-53, 2003.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568806
Filing Date	2006-02-26
First Named Inventor	Daniel HARARI
Art Unit	1646
Examiner Name	
Attorney Docket Number	HARARI=1

16	Mendelsohn J, et al., "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer", J Clin Oncol. 2003 Jul 15;21(14):2787-99	<input type="checkbox"/>
17	Schnepp, B., t al., "EGF domain swap converts a drosophila EGF receptor activator into an inhibitor.", Genes Dev, 12 (7):908-913, 1998	<input type="checkbox"/>
18	Shilo, B.Z. "Signaling by the Drosophila epidermal growth factor receptor pathway during development.", Exp Cell Res, 284(1):140-149, 2003	<input type="checkbox"/>
19	Strachan, L., et al., "Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily", J Biol Chem, 276(21):18265-18271, 2001	<input type="checkbox"/>
20	Summerfield, A.E., et al., "Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor", J. Biol. Chem., 271:19656-19659, 1996.	<input type="checkbox"/>
21	Tzahar, E., et al., "Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network", Embo J, 17 (20):5948-5963, 1998	<input type="checkbox"/>
22	Vinos, J., et al., "Evidence that Argos is an antagonistic ligand of the EGF receptor", Oncogene, 19(31):3560-3562, 2000	<input type="checkbox"/>
23	Yarden, Y., et al., "Untangling the ErbB signalling network", Nat Rev Mol Cell Biol, 2:127-137, 2001	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.